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Abstract: Cannabis is the illicit drug with both the largest current levels of consumption and the high-
est reported lifetime prevalence levels in the world. Across different countries, the prevalence of can-
nabis use varies according to the individual income, with the highest use being reported in North 
America, Australia and Europe. Despite its ‘soft drug’ reputation, cannabis misuse may be associated 
with several acute and chronic adverse effects. The present article aims at reviewing several papers on 
epidemiological, neurobiological and psychopathological aspects of the use of cannabis. The PubMed 
database was here examined in order to collect and discuss a range of identified papers. Cannabis in-
take usually starts during late adolescence/early adulthood (15-24 years) and drastically decreases in 
adulthood with the acquisition of working, familiar and social responsibilities. Clinical evidence sup-
ports the current socio-epidemiological alarm concerning the increased consumption among young-
sters and the risks related to the onset of psychotic disorders. The mechanism of action of cannabis 
presents some analogies with other abused drugs, e.g. opiates. Furthermore, it has been well demon-
strated that cannabis intake in adolescence may facilitate the transition to the use and/or abuse of other 
psychotropic drugs, hence properly being considered a ‘gateway drug’. Some considerations on syn-
thetic cannabimimetics are provided here as well. In conclusion, the highest prevalence of cannabis 
use and the social perception of a relatively low associated risk are in contrast with current knowledge 
based on biological and clinical evidence. Indeed, there are concerns relating to cannabis intake asso-
ciation with detrimental effects on both cognitive impairment and mental health. 
 
 
Keywords: Addiction, cannabimimetics, cannabis, delta-9-tetrahydrocannabinol, dopamine, gateway hypothesis, medical mari-
juana. 
1. INTRODUCTION 
 The plant of cannabis, also known as Canapa, Indian 
canapa, Marijuana, Mary Jane, Hashish, pot, herb, Maria, 
Hagga, Puf, Maconha, etc., belongs to the family of the 
Cannabinaceae and it is native to Central Asia. According to 
its botanical profile, cannabis may include several sub-
species and sub-varieties of the plant (e.g., Cannabis sativa, 
C. indica, C. ruderalis) [1]. It is found both as a naturally grown 
 
*Address for correspondence: Psychopharmacology, Drug Misuse and 
Novel Psychoactive Substances Research Unit, School of Life and Medical 
Sciences, College Lane Campus, University of Hertfordshire, Hatfield, Herts, 
AL10 9AB, UK; Tel: (+44) 0208 731 3003; Fax: +44 (0) 1707-284506;  
E-mail: f.schifano@herts.ac.uk 
product but also as the result of direct cultivation. Some va-
rieties of cannabis are specifically cultivated in order to ob-
tain their resin extract, particularly in some countries with 
tropical climates (e.g., Caribbean, Latin America, Southeast 
Asia, India, etc.). Given its extreme adaptability to temperate 
climates and the spread/dissemination of its indoor hydro-
ponic cultivation, its production has spread to both the 
United States and most European countries [2, 3].  
 Different preparations and extracts have been obtained 
from the Cannabis sativa plant. Marijuana appears to be a 
mixture of the inflorescences and the pressed/dried leaves of 
the plant, in which the larger proportion of its active ingredi-
ent delta-9-tetrahydrocannabinol (Δ9-THC) may range from 
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0.5 to 5% (sinsemilla, variant without seeds) to 7-14% (se-
milla, variant with seeds), whilst the variant Dutch Neder-
weed, cultivated in the Netherlands, may contain higher con-
centrations (15-18%). Marijuana is usually smoked alone, 
mixed with tobacco or more rarely with hyoscyamus leaves. 
A more active product (called Hashish, or Charash or can-
nabis resin) is obtained from the resin extracted from the 
flowers and leaves located at the top of the female plant. 
Hashish retains variable Δ9-THC concentrations, ranging 
from 2 to 20%. The hashish oil (also called liquid cannabis) 
is an extract of Δ9-THC obtained through solvent extraction. 
The hashish oil usually contains Δ9-THC concentrations 
ranging from 15 to 60%. It can be usually added as drops to 
the marijuana cigarettes in order to enhance the effects. 
Bhang is a mixed preparation, consisting of dried leaves and 
flowering tops of the overgrown plants. Like marijuana, it is 
characterized by low levels of central effects, mainly due to 
its route of administration, since it is infused and ingested as 
a drink, almost exclusively in India. Ganja consists of a ho-
mogeneous mixture of resin and apical leaves of the flower-
ing tops of the female plants. It has an average content of Δ9-
THC of about 3%.  
 Overall, cannabis represents the illicit substance with the 
highest consumption levels worldwide, particularly among 
adolescents with a mean age of first intake that has drasti-
cally decreased over time [2]. The overall prevalence of can-
nabis consumption, abuse and dependence is extremely vari-
able across countries. Western Central Africa (12.4%), Oce-
ania (12.4%), North America (10.7%) and Central Western 
Europe (7.6%) are the geographical areas that present with 
the highest consumption levels [2, 4, 5]. The growing trend 
of pro drug websites and of the online vending shops may 
well have recently contributed to the increasing trend of con-
sumption in the population aged 15-19 [6]. Furthermore, 
recent studies seem to confirm that cannabis can be consid-
ered a ‘gateway drug’ (i.e., a ‘bridge drug’). Indeed, the early 
cannabis consumption, through a process of learning and 
reinforcement, may cause a ‘cerebral sensitization’ associ-
ated with a more positive attitude towards the consumption of 
drugs of abuse with higher levels of abuse potential [7-10].  
 The present paper aims at providing some scientific con-
siderations relating to the epidemiological, neurobiological 
and psychopathological aspects of cannabis use. Further 
data, regarding the recently emerged synthetic cannabinoids’ 
issues, will be here provided as well. 
2. METHODS/LITERATURE SEARCH STRATEGY 
 A literature search on PubMed was carried out using the 
following MeSH terms: “Cannabis”, “Marijuana”, “Syn-
thetic cannabinoids”. No language or time restrictions were 
placed on the electronic search, covering the period up to 
January 2017. No filters were applied to limit the retrieval 
process, although the primary focus here was on human stud-
ies. The references indicated in the most relevant articles 
selected were used as further sources. The search was per-
formed independently by MADL and CC; findings were then 
compared and discrepancies settled, if needed, with the su-
pervision of GDC. Data were then collected in order to ob-
tain relevant information regarding the epidemiological, neu-
robiological and psychopathological issues relating to the use 
and/or abuse of cannabis, its derivatives, and synthetic can-
nabinoids. 
3. PREVALENCE OF CANNABIS USE IN EUROPE 
 Based on the 2016 World Drug Report, global cannabis 
consumption has been stable in recent years. In 2014, about 
3.8% of the world population had used cannabis in the previ-
ous year, a proportion that has remained stable since 1998. 
The largest amounts of cannabis herbal seizures which took 
place in the Americas, but Europe, North Africa and the 
Middle East remain the principal markets for cannabis, with 
the largest amounts of cannabis resin having been seized in 
2014 in Western and Central Europe (about 40% of the total) 
[2].  
 According to the European Monitoring Centre [3], during 
2016 in Europe, 22% (70 millions) of 15-64 years old indi-
viduals reported to have used cannabis at least once in their 
lifetime; 7% (23 millions) took it in the last year, and 4% (14 
millions) during the last month. In the 15-24 years old group, 
the last-month figure increases to 17%. As a comparison, 
cocaine use is around 10 times lower than cannabis use. The 
ESPAD survey, conducted in 2015 [11] across 35 European 
countries amongst students with an average age of 15.8 years 
reported that approximately 19% of males (M) and 14% of 
females (F) stated that they had consumed cannabis at least 
once, with peaks of 48% M vs. 38% F in the Czech Republic 
and 39% M vs. 40% F in France. Moreover, an average last-
month prevalence of around 8% in M and 5% in F has been 
reported, with an M/F ratio of 22.5% in France, 18% in the 
USA and 15% in the Czech Republic and Spain. In particu-
lar, according to “Monitoring the Future” study, e.g. a survey 
of the University of Michigan funded by NIH-NIDA, the 
annual prevalence of use for marijuana in the USA among 
full-time college students during 2015 was 37.9 % (40.2% in 
M and 36.6% in F) [12]. Furthermore, it has been demon-
strated that the lifetime prevalence of cannabis use in Europe 
has increased, between 1995 and 2011, by 6%. According to 
the last EMCDDA report [3], cannabis represents the most 
common primary drug, after heroin, amongst those patients 
who undergo specialist treatment of drug dependence and it 
is the most frequently reported drug amongst those undergo-
ing addiction treatment for the first time. In fact, in Europe, 
the number of cannabis consumers who started proper addic-
tion treatment for the first time increased by approximately 
45,000 in 2006 to 60,000 in 2011.  
3.1. A Three-Stage Model: Availability, Use, and Abuse 
 Genetic epidemiology studies conducted in twins demon-
strated that substance abuse depends on both genetic and 
environmental factors, with the latter being categorized into 
shared and non-shared between subjects. These three types 
of factors, in turn, may act on each of the stages that repre-
sent the natural history of substance dependence, i.e., avail-
ability, use, and abuse. Recently, Verweij et al. [13] con-
ducted a meta-analysis of studies focusing on the use and 
abuse of cannabis in twins. They found that genetic factors 
accounted for about 50% of the variance, both for the initia-
tion and the problematic use of cannabis. The remaining 
50% was divided between the risk of environmental, shared 
and non-shared, factors. A typical issue in cannabis use is 
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that the drug is frequently offered by most experienced con-
sumers to ‘novices’. Hence, as expected, initiation into can-
nabis use is directly related to its availability [14]. Gillespie 
et al. [15] studied, in twins, the drug initiation and abuse 
issues and their relationship with cannabis availability, ge-
netic and environmental, shared and non-shared, factors. 
Findings were consistent with a model in which cannabis 
availability may act on its initiation through shared environ-
mental factors, whilst cannabis initiation may facilitate start 
of abuse through the non-shared environmental, and genetic, 
factors. Thus, prevalence of use and availability are inextri-
cably linked and appear to influence each other. This rela-
tionship, magnified by the influence of the dynamics of the 
group, family, and social relationships which are typical of 
adolescence may, at least in part, explain the high prevalence 
of cannabis use amongst adolescents. 
3.2. Global Burden of Disease 
 The notion of the Global Burden of Disease (GBD) was 
firstly introduced by the World Bank to assess the socio-
economic impact of diseases and disorders. GBD is ex-
pressed in terms of years spent in disability (YLD), and years 
of life lost (YLL) that can be combined into years lost ad-
justed to disability (DALYs). Since GBD resulting from sub-
stance dependence is sensitive not only to the potential for 
abuse of a specific drug but also to its availability, the DALY 
expresses, better than any other indices, the socio-economic 
impact. Fig. (1) shows that cannabis dependence cause more 
DALYs than cocaine dependence. However, other data show 
that in countries with higher per person income the burden 
resulting from addiction to cannabis in 2010 was higher than 
that resulting from addiction to amphetamines (DALYs in 
millions of years: Australasia 9.3 to 5.8, Western Europe 4.3 
vs. 3.4, North America 8.1 vs. 3.3 [16].  
4. ABUSE POTENTIAL 
 Cannabis is commonly considered a ''soft'' drug. This 
expression was proposed in the late 60s, when the cannabis 
began to spread amongst youngsters. At that time, it was 
known only that Δ9-THC represented the active ingredient 
of cannabis [17, 18]. It took 20 years to discover and under-
stand its mechanism of action and its analogies with other 
misusing drugs [19, 20]. Unlike other illegal drugs, cannabis 
has been virtually considered devoid of lethal effects, a con-
sideration which has significantly contributed to its connota-
tion of being a “soft” drug, which is in contrast with the last 
10-year evidence from both epidemiological and clinical 
studies. The ESPAD report (2015), in which the question-
naire was administered to students (average age: 15.8 years), 
found that, amongst those who had consumed cannabis in the 
last year, the 33% individuals (36% M and 29% F) showed a 
problematic pattern of use such as early onset and daily 
smoking [11]. These findings have been confirmed by a pro-
spective study carried out by van der Pol et al. (2013) in a 
cohort of 600 daily cannabis users [21]. The authors ob-
served a cumulative incidence of dependence, over three 
years, of around 37%. 
 The abuse potential of a drug can be expressed in terms 
of percentage probability of transition from use to ‘problem-
atic’ use, i.e., abuse and addiction. A German longitudinal 
study [22], carried out in a sample of subjects between 14 
and 24 years-old subjects, observed a probability of transi-
tion from first use to dependence at 36% for nicotine, 11.2% 
for alcohol and 6.2% for cannabis. The probability of transi-
tion from use to abuse was of around 25.3% for alcohol and 
18.3% for cannabis. Furthermore, Lopez-Quintero et al. 
(2011) evaluated all data coming from the USA National 
Epidemiologic Survey on Alcohol and Related Conditions 
(NESARC) in terms of the cumulative probability of transi-
  
Fig. (1). Global epidemiology and contribution of cannabis use and dependence to the Global Burden of Disease (GBD). The proportion of 
years lost adjusted to disability (DALYs) due to cannabis dependence relative to other substance use disorders in GBD 2010. Adapted from 
Degenhardt et al. 2013 [16]. 
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tion from first use to dependence for cannabis, nicotine, al-
cohol and cocaine by reporting a probability of around 2% 
for cannabis, nicotine and alcohol [23]. The authors reported 
a percentage of around 15.6% for nicotine, 14.8% for co-
caine, 11.0% for alcohol and 5.9% for cannabis ten years 
after initiation of use, Overall, the authors reported as well a 
lifetime prevalence of transition of 67.5% for nicotine, 
22.7% for alcohol, 20.9% for cocaine and 8.9% for cannabis. 
Wagner and Anthony (2007) evaluated the latency of canna-
bis, alcohol and cocaine addiction onset, in 15 to 44-years 
old subjects [24] (Fig. 2). Regarding cannabis, dependence 
developed differently between M and F subjects, with a peak 
(max 4%) after three years of use in M and a lower plateau 
(max <1%) between 0.5 and 4.5 years in F (Fig. 2 A). Simi-
lar results were observed for alcohol (Fig. 2 B). Conversely, 
the latency of addiction to cocaine (Fig. 2 C) had a similar 
pattern in both sexes, with an earlier (1 year) peak compared 
to cannabis and alcohol. Overall, in terms of cumulative 
probability of dependence, cannabis addiction may reach its 
highest prevalence levels (approximately 14%) during the 
30s for M subjects, whilst cocaine addiction shows an in-
creasing trend up to when the subjects are in their 40s (max 
22%), and alcohol addiction may increase beyond the mid-
40s (max 30%). A study by Wagner and Anthony (2007) 
[24] showed that the probability in the early onset of canna-
bis addiction has a very narrow ‘time window’ in M subjects, 
mainly due to a gender-specific genetic risk of developing 
cannabis dependence [25]. 
5. CANNABIS AS A “GATEWAY DRUG” 
 One of the most controversial issues in cannabis epide-
miology is relating to the probability that its use in adoles-
cence may facilitate the transition towards the use and/or 
abuse of other illicit drugs with a higher potential of abuse 
[26]. Several epidemiological studies showed that early can-
nabis consumption may be associated with a higher, later, 
risk of abuse and/or dependence not only to cannabis but 
also to other illicit drugs such as cocaine, methamphetamine, 
and heroin [27, 28]. Various mechanisms have been pro-
posed to shed light on this correlation. Although not explic-
itly, the ‘gateway hypothesis’ states that the relationship be-
tween the intake of cannabis and that of drugs with a higher 
potential of abuse appears to be direct, mainly due to the 
properties of cannabis [26]. Conversely, others have sug-
gested that the association between the use of cannabis and 
that of other drugs may result from a combination of indi-
vidual factors such as genetic and environmental ones (com-
mon liability). For example, a reduced impulse control, or a 
greater tendency to seek gratification (reward seeking), due 
to genetic factors, could lead to a significant individual vul-
nerability towards the use of other drugs. Another hypothe-
sis, proposed by Wagner and Anthony (2002) [24], sug-
gested that people who use cannabis had a greater opportu-
nity to be exposed to other drugs commonly sold in the 
same, shared, ‘illegal market’. Overall, the ‘causal relation-
ship’ hypothesis is very controversial because the existing 
genetic and environmental factors may act as ‘potential con-
founders’. For this reason, some studies used statistical 
methods (e.g., the ‘Fitting model’) [29], whilst others com-
pared the risk of dependence within pairs of identical twins, 
with the same genetic background, who lived in the same 
family environment, but with a different pattern of cannabis 
use in adolescence [30, 31]. In both cases, the early use of 
cannabis resulted in a probability of abuse of other illicit 
drugs up to 2-5 times greater compared to subjects not ex-
posed to cannabis. However, even though the approach of 
Linskey et al. [30] excluded the role of genetic and environ-
mental (family) factors shared by both twins, it did not allow 
to exclude the relevance of the role of individual environ-
 
 
Fig. (2). Estimated risk for developing cannabis (A), alcohol (B) and cocaine (C) dependence by males versus females and time since first 
use, among 15-44 years old cannabis users. Data from the U.S. National Comorbidity Survey, 1990-1992. Adapted from Wagner and An-
tony, 2007 [24].  
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mental factors not shared among twins. These limitations 
may have been better controlled by the longitudinal study of 
Lessem et al. [32], which included both twins and brothers/ 
sisters and which confirmed the Linskey et al. findings [30]. 
Therefore, the current hypothesis is that the use and abuse of 
cannabis in adolescence may well predispose to the use and 
abuse of drugs with a higher potential of abuse. Lessem et al. 
[32] suggested that the use of cannabis may cause ‘the fall of 
a taboo’, paving the way for other, more powerful and dan-
gerous, drugs. Whilst considering the hypothesis that the use 
of cannabis may predispose to the use of ‘harder drugs’, the 
United States promoted a campaign for the prevention of 
cannabis availability and use in adolescence. 
6. MEDICAL MARIJUANA  
 Recently, both several states of the USA and the District 
of Columbia (May, 2015) approved a range of laws to pro-
tect the prescription/sale/use of cannabis for therapeutic use 
from the federal justice. Some states also endorsed laws that 
protect the dispensaries of marijuana for therapeutic use 
from the federal justice. Kleber and DuPont (2012) high-
lighted the totally abnormal aspects of ‘medical marijuana’ 
[33]. First at all, it is abnormal that it is a smoked medica-
tion. In fact, there is no FDA-approved drug administered by 
this way. The main reasons are obvious enough, since mari-
juana smoking is more dangerous than tobacco, and it is not 
possible to self-administer with precise dosages. Therefore, 
smoking does not deliver a reproducible and predictable dos-
age between different subjects as well as in the same subject, 
due to the differences in the Δ9-THC percentages in the dif-
ferent preparations of marijuana and Δ9-THC extraction ef-
ficiency among different people and situations. As reported 
by Kleber and DuPont (2012): “Medical marijuana bypasses 
the century-old, scientifically based, drug approval proce-
dure and the carefully regulated distribution of medications 
through licensed pharmacies’ [33]. The fact that marijuana 
has been introduced as a medical treatment after a referen-
dum and a political decision, bypassing all the rules which 
drugs are subjected to, establishes a dangerous precedent for 
public health. The fact that smoking is a pharmacotherapeu-
tic non-sense, whilst it is the common mode of cannabis use 
for recreational purposes, is symptomatic of the fact that the 
so-called ‘medical marijuana’ is nothing more than a short-
cut for legal recreational use of cannabis. In fact, less than 
5% individuals authorized to purchase medical marijuana 
suffer from those conditions that may justify its compassion-
ate use (e.g., HIV, cancer, multiple sclerosis) [34]. Currently, 
the most frequent justification for medical marijuana pre-
scription is the treatment of pain (82-87%), anxiety (38%), 
and depression (26%) [34, 35]. Moreover, it has been re-
ported that 96% of medical marijuana enthusiasts had used 
cannabis in their lifetime, whilst in the general population 
this figure is 4 times less. In addition, other medical cannabis 
preparations include cannabis tea and cannabis oil that, the 
most of the time, are not standardized preparation, thus not 
ensuring a homogeneous product of defined stability [36]. 
Recently, a systematic review of the side effects of cannabi-
noids for medical use including 79 clinical trials have shown 
an increased risk of short-term adverse events (e.g., dizzi-
ness, dry mouth, nausea, fatigue, somnolence, euphoria, 
vomiting, confusion, hallucinations) compared to associated 
benefits [37]. In Europe, cannabis preparations such as Sa-
tivex and Bedrocan are already available, and several Euro-
pean countries are able to supply patients with medicinal 
cannabis. Italy, after a trial period of two years, approved the 
pharmacies’ sale of the whole-plant cannabis, or cannabis-
based drugs produced by the state, upon presentation of a 
medical prescription. 
7. THE IMPACT OF LEGALIZATION 
 In November 2016, California, Massachusetts and Ne-
vada legalized the recreational use of cannabis. In Europe, 
none of the EU Member supports completely the legalization 
of cannabis sale for recreational use, but over one third (e.g., 
Czech Republic, Belgium, Denmark Italy, Latvia, Lithuania, 
Luxembourg, Malta, Croatia, and Slovenia) act a “depenali-
zation” and “decriminalization” approach of its personal 
possessions, whilst others (e.g., Spain, Germany, Portugal, 
and the Netherlands) allow the use and sale of small amounts 
through special dispensaries, recreational stores (coffee 
shops) and clubs. From a scientific point of view, the legali-
zation of cannabis is both a natural experiment and a large-
scale business. However, it is likely that the legalization of 
cannabis will have consequences on physical and mental 
health, although the effects of cannabis legalization on health 
could be detected only after several years.A number of stud-
ies focused on some aspects of the cannabis market, such as 
the extent of demand and supply (production), the price, the 
Δ9-THC content and its consumption,. According to Pacula 
and Sevigny (2014), the differences in legislation between 
the States and the continuous legislative changes, in the same 
states, make it difficult to draw general conclusions [38]. 
Indeed, the available evidence suggests that the two markets, 
legal and illegal, are closely interrelated, especially when the 
control is loose. From this point of view, Rendon (2013, p. 
147) wrote, “the legalization of marijuana for medical use in 
California has changed everything about the market for pot 
and is pushing changes for growers, breeders, and the plant 
itself” [39]. Substantial amounts of medical marijuana are 
produced in excess and diverted to the illegal market. In 
Colorado, a recent investigation documented dozens of cases 
of diversion of cannabis to the illegal market from dispensa-
ries, patients and authorized physicians (Investigative Sup-
port Center, 2012). Data relating to the effects of the legali-
zation on cannabis use, expressed as prevalence and there-
fore on the number of users, are not univocal, since the num-
ber of studies indicating an increase is equal to the number of 
studies that did not find any significant changes. However, 
there is no doubt that, by expressing the use in terms of 
quantity self-administered, legalization has been associated 
with an increase in consumption amongst regular users. 
Pacula and Sevigny (2014) observed that the effects of le-
galization on cannabis use depends on social (e.g. changes in 
social norms or in perceived risk), environmental (local pres-
ence of dispensaries and ease of access to cannabis), and 
market factors (scale of production and price) [38]. For ex-
ample, an increase in demand due to the first two factors will 
produce an increase in price, which, in turns, will tend to 
limit the use. Conversely, an increase in the production of 
cannabis, by reducing the price, would promote its dissemi-
nation and use. Another possible consequence of the legali-
zation of cannabis relates to the influence on alcohol con-
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sumption. Alcohol and marijuana may be complementary, 
being consumed either jointly, or alternatively. In the first 
case, the effects on driving is quite negative, since alcohol 
and cannabis act on two different driving modes, respec-
tively outcome-related and habitual, each of which can, in an 
asymmetric way, compensate in case of dysfunction of the 
other. In the second case alcohol, by impairing the executive 
functions, exerts the most severe effects. However, cannabis 
may force the subject to shift on the outcome-dependent 
mode, by interfering with the habit mode. In this case, the 
choice of alcohol or cannabis by adolescents/young adults 
depends on the price. According to Anderson and Rees 
(2014), the legalization of cannabis led to a substitution of 
alcohol with cannabis in those States in which a reduction of 
the cannabis price was reported, due to an excessive produc-
tion, and a convenience of cannabis compared to alcohol 
[40]. However, this consideration has been questioned by 
Sevigny and Pacula (2014) [38]. Quite recently it has been 
reported that among 8th and 10th graders, in Washington 
state, perceived harmfulness of marijuana use decreased, and 
marijuana use increased, following the legalization of recrea-
tional marijuana use [39]. In contrast, Colorado did not ex-
hibit any differential change in perceived harmfulness or 
past-month adolescent marijuana use following legalization. 
This difference may be related to the different degree of 
commercialization of marijuana prior to legalization in 
Washington and Colorado. Colorado had a very developed 
medical marijuana dispensary system prior to legalization, 
with substantial advertising, to which youths were already 
exposed. Washington, on the other hand, was not previously 
providing legal protection to medical marijuana stores. 
Therefore, the degree of commercialization and advertising 
of these dispensaries was substantially lower than in Colo-
rado. In addition, rates of perceived harmfulness in Colorado 
were already lower and rates of marijuana use were already 
higher than rates in Washington and non-legalizing states 
prior to legalization. The longer-term effect of legalization 
implementation on adolescent marijuana use in Colorado is 
still to be determined [41]. 
8. LEVELS OF Δ9-THC IN CANNABIS PRODUCTS 
 The effects of cannabis mainly depend on its Δ9-THC 
content. Indeed, several studies reported that, amongst can-
nabis consumers, the risk of occurrence of psychopathologi-
cal disturbances, including anxiety, psychosis, and cognitive 
disturbances appears to be correlated to cannabis potency/Δ9-
THCcontent. Over the last 30 years, the Δ9-THCcontent in 
cannabis herbal crops and products has progressively in-
creased worldwide. In the United States, for example, the Δ9-
THC content in marijuana was 2% in 1980, 4.5% in 1997, 
8.5% in 2007 and 9.6% in 2010.  
 According to the latest EMCDDA report [3], the Δ9-THC 
content in marijuana and hashish is of 7-8% (ranging from 
2% to 16%) on average. However, the cannabis market ap-
pears to be more volatile than what described by the above 
data. In fact, the introduction of cannabis preparations ob-
tained through unique, in house, cultivation techniques, e.g. 
by preventing female flowers pollination (sinsemilla), or 
obtained by breeding plants cultivated in artificial conditions 
(hydroculture), has radically modified the ‘cannabis market’ 
and, hence, its Δ9-THC content. Sifaneck and co-workers 
[42] described the cannabis scenario in New York City 
where, in addition to the open field-cultivated commercial 
marijuana, the so-called ‘designer marijuana’, is available. 
Designer products (e.g., ‘Haze’, ‘Skunk’, ‘White Widow’), 
obtained by local crops in artificial conditions, are more ex-
pensive, but can be acquired by credit card with a toll-free 
call and delivered at home. 
 Notably, in the Netherlands, an increase of Δ9-THC con-
tent in cannabis products has been associated with cannabis 
legalization. Pijlman et al. [43] studied the Δ9-THC percent-
age in both imported marijuana/hashish and in their derived 
preparations, Nederwijete Nederhasij, obtained from locally 
cultivated selected species, both sold in Amsterdam ‘Coffee 
Shops’. Imported marijuana and hashish showed an increase 
in Δ9-THC content (respectively: 5% and 11%, in 2000; 7% 
and 18.4%, in 2004), whilst the locally produced marijuana 
and hashish changed their Δ9-THC content, respectively, 
from 8.6% and 20.7% in 2000 to 20.4% and 39.3% in 2004. 
Since 2004, the Δ9-THC potency has remained at these levels 
[4]. In the US, a smaller level of increase (e.g., of about 1%) 
in Δ9-THC content has been observed in preparations sold in 
the illegal market in those States where legalization has been 
accompanied by establishing authorized dispensaries, nick-
named as ‘Cannabis supermarkets’ [44]. 
9. CANNABIS WITHDRAWAL SYNDROME 
 A chronic cannabis consumption may be conceived as a 
Cannabis Use Disorder (CUD) based on specific criteria of 
both DSM-IV and DSM-V. However, the cannabis capacity 
to induce both physical dependence and withdrawal syn-
drome after quitting its use was introduced only with the 
DSM-V [45]. A proper withdrawal syndrome may be ob-
served in about one third of regular cannabis users and in 
around 50-95% of the individuals who consume high dos-
ages of cannabis in experimental contexts [45]. The cannabis 
withdrawal syndrome is characterized by craving, irritability 
and aggressiveness, dysphoria, depressed mood, anorexia, 
sleep disturbances/weird dreams, and motor disturbances. 
Physical signs/symptoms are less intense when compared to 
those observed during an alcohol or heroin withdrawal syn-
drome, but the craving has been reported as possibly more 
intense [45-47]. 
 Tolerance and physical dependence to cannabis may be 
rapidly induced in laboratory animals, where it may be pre-
cipitated by the administration of rimonabant, an antagonist 
of cannabinoid CB1 receptors. In experimental animals, the 
behavioural features of a cannabis withdrawal syndrome are 
reminiscent of an opiate withdrawal syndrome. Like heroin 
and cocaine, the cannabis withdrawal syndrome may be as-
sociated with a reduction of dopaminergic turnover in the 
nucleus accumbens shell (see below) [48, 49]. 
10. CANNABIS REINFORCING PROPERTIES 
 The studies investigating the behavioural and reinforcing 
properties of the drugs of abuse in experimental animals 
have a fundamental importance in understanding the mecha-
nisms by which these substances may induce a dependence 
status in humans. 
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 A fundamental property, common to all drugs of abuse, is 
that cannabis may act as a behavioural reinforcer and can 
hence be self-administered by laboratory animals. Any effort 
made to obtain a self-administration of the active component 
of cannabis, Δ9-THC, in different animal species, from pri-
mates to rodents, has proved to be a complex task. However, 
Δ9-THC may be self-administered intravenously by monkeys 
(squirrel monkeys), e.g. both those previously trained to self-
administer with cocaine and by naive ones as well [50, 51]. 
Δ9-THC doses producing this effect are around 4 micro-
grams/kg. In the rat, the intravenous self-administration has 
been obtained with WIN 512,212-2, a synthetic agonist of 
cannabinoid CB1 receptors, but not with Δ9-THC itself [52, 
53]. The reason of this discrepancy is likely to be due to the 
peculiar Δ9-THC pharmacokinetics in the rat, which does not 
allow the maintenance of a strict temporal contingency be-
tween operant responding and the rewarding effects of the 
drug, which is an essential condition for the acquisition of a 
reinforced behaviour. 
11. STIMULATION OF DOPAMINE TRANSMISSION 
 THC is able to stimulate dopamine (DA) release in the 
ventral striatum, preferentially in the shell of nucleus accum-
bens. This property, relating to both Δ9-THC and its syn-
thetic analogue, WIN 512,212-2, has been demonstrated by 
means of different techniques both in rats, following passive 
(microdialysis and fast scan cyclic voltammetry) [49, 54-56], 
and active self-administration [53], and in humans (C11-
raclopride binding measured by PET [57, 58]).  
 The maximal stimulation of DA release by Δ9-THC ad-
ministered intravenously is quantitatively similar to that in-
duced by heroin [49]. These effects are blocked by an an-
tagonist of the CB1 receptors as well as by an antagonist of 
opioid receptors, naloxonazine, at the same doses which are 
able to block the stimulation of DA transmission by heroin 
[49]. The stimulant effects of Δ9-THC on DA transmission 
are due to a stimulation of firing activity of mesencephalic 
DA neurons projecting to the nucleus accumbens [59]. Given 
that opioid receptors blockade should also prevent the Δ9-
THC self-administration in monkey [60], these findings, 
together with the demonstration that Δ9-THC releases beta-
endorphins [61], may suggest that cannabis may release en-
dogenous opioids acting on mu receptors. This effect may 
contribute to both Δ9-THC reinforcing properties and the 
ability to release DA in the nucleus accumbens (Fig. 3). 
 The ability of Δ9-THC to stimulate DA transmission in 
the shell of nucleus accumbens is common not only to heroin 
and opiates but also to all drugs of abuse (e.g., psychostimu-
lants/nicotine/alcohol) [62]. These findings may suggest that 
DA plays a role in the reinforcing properties of cannabis and, 
in general, of all drugs of abuse. The DA in the nucleus ac-
cumbens shell possesses different functions. Among these, 
there is the ability to facilitate acquisition and expression of 
incentive properties by conditioned Pavlovian stimuli. Ex-
perimental studies on behavioural and biochemical proper-
ties of Δ9-THC and its synthetic analogues confirm the status 
of cannabis as a substance possessing the ability to induce 
dependence not differently from other drugs, commonly de-
fined as ‘hard drugs’.  
12. NEUROBIOLOGY OF CANNABIS AS A GATE-
WAY DRUG 
 The existence of a causal relationship between cannabis 
intake and the following use of other ‘hard drugs’ may be 
studied and discussed in animal models as well.  
 From a neurobiological point of view, the more consis-
tent relationship is between cannabis and heroin. Indeed, 
these drugs share a range of common pharmacological prop-
erties which are mediated by their stimulation of mu opioid 
receptors and which are in turn strictly correlated with their 
ability to induce dependence, facilitate self-administration, 
and the ability to stimulate DA release in the nucleus accum-
bens shell (see above). Moreover, previous exposure to Δ9-
THC or other synthetic cannabinoid agonists has been re-
ported to sensitize to the stimulant motor effects (behav-
ioural sensitization) of both Δ9-THC and morphine, but not 
of psychostimulants (cocaine and amphetamine) and vice 
versa [63, 64]. Similarly, previous exposure to morphine 
induces sensitization to morphine but also to Δ9-THC (cross 
sensitization). 
 The most striking evidence of Δ9-THC ability, adminis-
tered during adolescence, to increase the rewarding and rein-
forcing properties of heroin has recently been provided [64]. 
Previous studies on this issue showed that Δ9-THC exposure 
during adolescence [65] or adulthood [66] may increase rates 
of responding in intravenous heroin self-administration para-
digms. The meaning of these findings is difficult to be inter-
preted since this might be suggestive of both an increase and 
a decrease of the reinforcing properties of heroin. Con-
versely, the Di Chiara et al. (2013) study used instead a pro-
gressive ratio paradigm, where the number of responses that 
the animal has to perform, in order to obtain an intravenous 
injection of the drug increased progressively [67]. The maximal 
number of responses the animal is able to emit (breaking 
point) is a measure of the ability of the drug to reinforce the 
behaviour. By using this paradigm, we observed that adoles-
cent pre-exposure to Δ9-THC increased the maximal number 
of responses the animals emitted and, thus, the heroin rein-
forcing properties. This effect was observed in the addiction-
prone Lewis rat strain, but not in the Fischer 344 one [56], 
and appears to be associated with a potentiation of DA re-
lease stimulation in the nucleus accumbens shell [53]. These 
results suggest that, similarly to what was hypothesized for 
the psychopathological effects, cannabis intake may be asso-
ciated with a vulnerability risk factor, likely genetic in na-
ture, which may facilitate the use and abuse of other illicit 
drugs with higher levels of abuse potential. 
13. CANNABIS AND PSYCHOPATHOLOGY 
 Cannabis intoxication, a transient condition that develops 
after the intake of the substance, is characterized by distur-
bances in level of consciousness, cognition, perception, af-
fect, behaviour, or coordination. Common intoxication signs 
and features include conjunctival injection, increased appe-
tite, dry mouth, tachycardia, euphoria, relaxation, perceptual 
alterations, suspiciousness, paranoia, intensification of ordi-
nary experiences, increased sociability, impaired short-term 
memory and attention, and impaired motor activity [68-70]. 
A disorder of regulation of cannabis use can arise from its 
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repeated or continuous use. A central feature of cannabis use 
disorder/dependence is a strong internal drive to use the sub-
stance, manifested by impaired ability to control use, in-
creasing priority given to cannabis use over other activities, 
and persistence of use despite harm and adverse conse-
quences [68, 70]. An amotivational syndrome has been de-
scribed in long-term cannabis users; the syndrome includes 
lack of motivation, apathy, social withdrawal, lethargy, im-
paired memory and concentration. It may resolve or improve 
with continuous abstinence [70]. Δ9-THC is known to pos-
sess psychotomimetic effects, and, indeed, its intravenous 
administration constitutes one of the current pharmacological 
models of psychosis [71-73]. The available evidence points 
to a causal role for Δ9-THC in schizophrenia spectrum disor-
ders [68] with a dose-response relationship between levels of 
Δ9-THC ingested and risk for psychosis having been postu-
lated [74]. The consumption of cannabis characterized by a 
high cannabidiol (CBD) content seems to be associated with 
fewer psychotic experiences [75]. On the other hand, the 
intake of highly Δ9-THC concentrated cannabis strains (e.g. 
12-18% of Δ9-THC, and no CBD) is associated with an in-
creased severity of cannabis dependence, higher risk for psy-
chotic disorders, and a lower age at onset of psychosis [68, 
76-78]. Acute cannabis-induced psychotic episodes are not 
uncommon in cannabis dependent individuals, and are char-
acterized by rapid onset, and relatively benign course follow-
ing cessation of use. Regular cannabis users may also expe-
rience repeated, short, episodes of psychosis and/or may re-
main in a pre-psychotic state. Cannabis use may precipitate 
psychotic symptoms in individuals vulnerable to psychosis, 
and in patients with schizophrenia may trigger a relapse/ 
exacerbate symptoms even with stable antipsychotic medica-
tions [79]. There is some evidence to support the statistical 
association between cannabis use and the increased inci-
dence of bipolar disorders. Cannabis use may lead to the 
onset of mania/hypomania symptoms, particularly among 
regular or daily users, and can moderate the course of bipolar 
disorder by increasing the time to recovery, relapse, and re-
currence of manic phases [80]. A heavy use of cannabis is 
associated with a small increase in the risk of developing 
depressive disorders. Increased levels of both suicidal idea-
tion and suicide attempts, and greater risk of death by sui-
cide, are also related to cannabis use [80]. Anxiety and panic 
attacks are cannabis common adverse effects, and can often 
happen in long-term cannabis users. 
14. SYNTHETIC CANNABINOIDS 
 Herbal preparations containing synthetic cannabinoids 
(SC) have been marketed since 2004, mainly online, as ‘legal 
alternatives’ to cannabis, under different names (‘Spice 
Gold’, ‘Spice Silver’, ‘nJoy’, ‘Blaze’, ‘Orange’, ‘Lilla’, 
‘K2’, etc.) [81-83]. In 2008, Spice/K2 products have become 
very popular in Germany, after several cases of intoxications 
[83, 84]. Spice preparations include inert or psychoactive 
plant materials (e.g., Leonotis leunurus, Pedicularis densi-
flora) laced with various synthetic SC, which are CB1 and 
CB2 receptor agonists, chemically and pharmacologically 
different from Δ9-THC. Indeed, Δ9-THC is a partial CB1 
agonist, whilst SCs are full agonists with a higher potency 
and efficacy as compared to Δ9-THC [85]. SC have been 
extensively studied and classified in three generations: the 
first includes Δ9-THC analogues (HU-210) but also aminoal-
kylindole and cyclohexylphenoles (e.g. JWH-018 series, 
WIN-55,212-2, and CP-47,497); the second generation in-
cludes alkyl derivatives (AM-2201, MAM-2201, AM-694), 
N-metilpiperidines (AM-2233 and AM-1220) and benzoin-
doles (AM-679, RCS-4 and derivatives); whilst the third 
generation includes molecules in which the indole ring is 
replaced with an indazole or a benzimidazole group (AKB-
48, 5F-AKB-48, FUBIMINA), or molecules where the car-
bonyl group is replaced with the carboxylic or carboxy-
amide functional group (APICA, SDB005), and quinolones 
(PB-22 or QUPIC, 5F-PB-22, BB-22 or QUCHIC) with sec-
ondary cyclic structures (ABDICA, AB- PINACA, 5F-AB-
PINACA) and new nitrogen groups (AB-FUBINACA, AB-
FUBICA) [86]. Smoking ‘Spice’ induces more intense and 
long-lasting euphoria compared to cannabis, frequently asso-
ciated with panic/anxiety states, paranoia, psychosis, halluci-
nations, seizures, tachycardia, headache, nausea, vomiting 
and a severe withdrawal [82, 87, 88]. The first SC to be iden-
tified (in 2008) was JWH-018 (1-Pentyl-1H-indol-3-yl)-1-
naphthalenylmethanone) which has been reported in more 
than 140 specimens of Spice both in Europe and in Japan 
[89, 90, 91], although in different amounts depending on the 
compound analysed. JWH-018 was synthesized in 1995 by 
 
 
Fig. (3). Effect of cannabis and opiates on dopamine (DA) transmission. The schema represents that opiates and cannabinoids stimulate DA 
release in the nucleus accumbens (NAc) by blocking the brake exerted by GABA neurons onto DA neurons in the Ventral Tegmental Area 
(VTA). CB1, cannabinoid receptors 1; MOR, µ-Opioid receptors. Adapted from Di Chiara et al., 2014 [105]. 
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John William Huffman at Clemson University (USA) as part 
of a structure-activity relationship study of the structural 
determinants of the CB1 versus CB2 receptor binding and 
intrinsic activity. Compared to Δ9-THC, JWH-018 exhibits 
an approximate four-fold higher affinity for CB1 (Ki ~ 9 nM) 
receptor and ten-fold affinity for the CB2 receptor (Ki ~ 3 
nM) [85, 92-94]. In vitro studies on liver microsomes [95] 
and in urine [96] showed the presence of several pharmacol-
ogical active metabolites [97]. The higher potency of JWH-
018 compared to Δ9-THC in vivo, and the formation of active 
metabolites, are likely to be the reason of Spice being able to 
induce a more severe dependence and withdrawal syndrome 
compared to cannabis. Recently, it has been suggested that 
rats and mice are able to consistently acquire levels of oper-
ant behaviour, resulting in JWH-018 self-administration 
[98]. This may well confirm the reinforcing properties of SC, 
which display a more robust intravenous self-administration 
compared to endocannabinoids or Δ9-THC [99]. JWH-018 
preferentially increased DA release in the NAc shell in vivo 
via CB1 receptors, thus linking JWH-018 to both other can-
nabinoids with known abuse potential, and to other classes of 
misusing drugs that increase DA signalling in the NAc shell 
[98]. Furthermore, recent studies showed that third genera-
tion SC molecules (e.g., 5F-PB-22 and BB-22), compared to 
JWH-018, possess an even higher CB1 receptor agonist po-
tency, five- and seven- fold, respectively; higher efficacy 
levels; and a higher binding affinity (26- and 30-fold, respec-
tively) at CB1 receptors. Moreover BB-22, the SC with the 
highest affinity for CB1 receptors among those tested, was 
able of stimulate DA release in the NAc shell at doses 10-
fold lower compared to JWH-018 [100]. Other studies 
showed that SC impair sensorimotor reflexes and produce 
aggressive behaviour in mice [101, 102]. The availability 
and rapid spread of Spice compounds have largely contrib-
uted to the change of the global scenario of cannabis con-
sumption. Despite the efforts to ban their sale, SC products 
continue to be easily purchased by anyone, irrespectively of 
age, and therefore represent a major risk for health [103, 104]. 
CONCLUSION 
 The issue of the legalization of cannabis can be looked up 
in different ways, depending on the perspective from which 
it is considered. From a social point of view, the legalization 
may well reduce the perception of cannabis as a danger, by 
increasing both its availability and consumption in adults. 
The economic liberalization, through the excise duty charged 
by the states, may well become a significant source of reve-
nues for the states involved. However, this approach may not 
extinguish at all the illicit market, which could even become 
more competitive than the legal one due to the amount of 
taxes levied by the states. Paradoxically, under-age subjects, 
who are also the largest consumers and those at higher risk 
of possible long-term effects of cannabis, for legal reasons 
cannot directly access the legal cannabis. Hence, they could 
be more exposed to cannabis because of its diversion from 
the legal to the illegal market. Therefore, apart from the pos-
sible economic benefits and tax advantages, the liberalization 
of cannabis may not seem at all to reduce the dangers of 
long-term sequelae on adolescents’ health. 
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